CHM round table

Swissmedic and the complementary and herbal medicine (CHM) industry and associations meet regularly to discuss topics relating to the regulation of medicinal products, and of complementary and herbal medicines in particular, at a Round Table on CHM (referred to below as the Round Table). The Round Table enables the various stakeholders to make their concerns heard in order to respond promptly and appropriately to regulatory and technical changes and signals, as necessary. Swissmedic is keen to discuss changes in the regulation of medicinal products with representatives of the CHM industry and associations before the changes are made, so that practical aspects of operational implementation can be properly taken into account and communicated appropriately to the target audience.

The Round Table comprises representatives of the CHM industry and its associations plus senior representatives of the Authorisation division at Swissmedic. Over the years, the direct exchange between Swissmedic and the CHM industry and associations in the context of the Round Table has proven to be a productive way of promoting mutual understanding of the different stakeholders’ concerns and of planning and implementing regulatory, process-related and technical changes and issues in an efficient manner.

The Round Table’s guidelines for cooperation are set out in the Terms of Reference (TOR).

Industry participants

A maximum of 12 representatives of the CHM industry and associations who are familiar with operational issues in the pharmaceutical industry on the basis of their day-to-day work or many years of experience take part in the Round Table. They also need to have in-depth knowledge of the legislation, the political environment and the working methods of Swissmedic.

The associations agree among themselves on their representatives at the Round Table. If you are interested in taking part, please first contact

The following people currently participate in the CHM Round Table:

Name Company / association
MSc. ETH Rahel Böhlen Schwabe Pharma AG; SVKH 
Andreas Eyholzer Geschäftsführer SVKH
Dr. Ursula Gebauer Regena AG; SVKH 
Patrick Gehrig Wala AG; SVKH 
Dr. Christiane Halbsguth Max Zeller Söhne AG; vips
Dipl. pharm. Christoph Kalbermatten Ceres AG; Vorstand SVKH
Dr. Monica Mennet Weleda AG; Vorstand SVKH
Dr. Katharina Oehler-Tomamichel Pharma-Services Oehler GmbH; SMGP
Dr. med. Gesa Otti-Rosebrock Praxis Frauenmedizin Biel; Vorstand SMGP
Florian Pelzer Iscador AG; SVKH
MSc. ETH Luzia Rüdlinger vips
Dr. Herbert Schwabl Padma AG; Präsident SVKH